Top Page
HitIQ Limited
(Sydney:HIQ)
HitIQ Limited (HIQ) vs. iShares MSCI Australia ETF (EWA)
HitIQ Limited Business Overview & Revenue Model
HitIQ Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.01M | 2.01M | 4.75M | 774.26K | 619.02K | 406.68K |
| Gross Profit | -2.18M | -2.18M | 334.63K | 242.73K | 243.43K | -3.28M |
| EBITDA | -5.99M | -5.99M | -2.54M | -4.31M | -6.54M | -4.79M |
| Net Income | -7.21M | -7.21M | -3.20M | -5.04M | -6.95M | -5.06M |
Balance Sheet | ||||||
| Total Assets | 3.28M | 3.28M | 3.73M | 3.13M | 4.55M | 9.49M |
| Cash, Cash Equivalents and Short-Term Investments | 990.96K | 990.96K | 584.02K | 1.98M | 2.94M | 8.96M |
| Total Debt | 5.66M | 5.66M | 3.20M | 1.69M | 2.16M | 709.34K |
| Total Liabilities | 7.30M | 7.30M | 5.20M | 3.18M | 3.38M | 1.56M |
| Stockholders Equity | -4.02M | -4.02M | -1.47M | -46.86K | 1.17M | 7.92M |
Cash Flow | ||||||
| Free Cash Flow | -4.68M | -4.68M | -4.12M | -4.57M | -6.57M | -2.18M |
| Operating Cash Flow | -4.65M | -4.65M | -4.10M | -4.51M | -6.51M | -2.13M |
| Investing Cash Flow | -28.57K | -28.57K | -20.78K | -54.73K | -918.06K | -54.84K |
| Financing Cash Flow | 5.09M | 5.09M | 2.73M | 3.61M | 1.41M | 10.71M |
HitIQ Limited Technical Analysis
HitIQ Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$21.84M | -12.11 | -17.05% | ― | 28.91% | -1050.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$10.04M | -1.09 | ― | ― | -40.05% | -49.57% | |
41 Neutral | AU$5.22M | -5.91 | ― | ― | -9.90% | 34.07% | |
41 Neutral | AU$43.43M | -7.57 | -81.30% | ― | -36.68% | 79.41% | |
40 Underperform | AU$78.49M | -10.79 | ― | ― | ― | ― | |
34 Underperform | AU$15.55M | -4.79 | ― | ― | 241.34% | 44.19% |
HitIQ Limited Corporate Events
HitIQ Limited has announced a proposed issue of securities, including 29,431,818 options expiring on December 30, 2028, and 42,045,455 ordinary fully paid shares. This issuance is part of a strategic move to strengthen the company’s financial position and support its growth initiatives. The announcement reflects HitIQ’s commitment to expanding its market presence and enhancing its operational capabilities, which could have significant implications for its stakeholders and industry positioning.
HITIQ Limited has successfully completed an oversubscribed placement, raising $925,000 from new and existing sophisticated investors. The funds will be used for the ongoing development and commercialization of its concussion management technology and general working capital. This capital raise, which follows a recent rights issue, positions HITIQ with a solid financial base as it heads into 2026, and underscores the growing momentum and investor confidence in its concussion management solutions.
HitIQ Limited has requested a trading halt on its securities pending an announcement regarding a capital raising initiative. This move is intended to help the company manage its disclosure obligations and is expected to impact its financial operations, potentially influencing its market positioning and stakeholder interests.
HitIQ Limited, listed on the ASX under the ticker HIQ, held its 2025 Annual General Meeting on Friday, 28 November. The meeting’s agenda included discussions on the 2025 financial statements, a poll on twelve resolutions, and an executive chair presentation, followed by a general Q&A session and refreshments. The event aimed to address key business matters and engage stakeholders in the company’s strategic direction.
HITIQ Limited has announced the retail distribution of its PROTEQT™ concussion management system through rebel, Australia’s leading sporting goods retailer. This strategic move marks HITIQ’s entry into the consumer retail market, leveraging rebel’s extensive retail network and brand recognition. The collaboration with Shock Doctor has facilitated this transition, positioning PROTEQT™ for availability ahead of the 2026 sports season. This initiative aims to capture the growing demand for safety products in contact sports, driven by increased safety awareness and regulatory focus on athlete safety.
HITIQ Limited has announced its strategic entry into the North American market through a partnership with Rick Shultz, who will serve as the exclusive distributor for PROTEQT™ mouthguards in Canada and hold non-exclusive rights in the United States. This move leverages Shultz’s extensive connections within the Canadian hockey ecosystem, aiming to capitalize on the country’s substantial hockey market, which is the second-largest globally. The partnership is expected to generate immediate revenue and support long-term growth, with a focus on both institutional and consumer channels to address the full spectrum of the market. The strategy underscores HITIQ’s commitment to expanding its presence in North America and meeting the growing demand for concussion management technology.
HitIQ Limited announced a change in the director’s interest notice involving Matthew Clayworth. The notice details adjustments in the number of securities held by Clayworth, primarily due to corrections of administrative errors and the expiration of certain options. This change reflects a routine update in the company’s governance and does not imply immediate operational or strategic shifts.
HitIQ Limited has announced the quotation of 400,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of November 14, 2025. This move is part of their strategy to enhance liquidity and provide more opportunities for investors, potentially strengthening their position in the market and benefiting stakeholders by increasing the company’s visibility and capital resources.
HITIQ Limited’s PROTEQT™ technology has been selected for a major brain injury research program funded by the Australian Research Council (ARC) and led by Monash University. The project, which has secured a grant of $799,866, will utilize 400 PROTEQT™ units to study brain injury thresholds, combining biomechanics and biomarkers. This partnership not only provides immediate revenue but also positions HITIQ at the forefront of concussion research, potentially influencing global safety protocols and clinical guidelines. The collaboration enhances HITIQ’s reputation and supports its regulatory pathways, with implications for international adoption and validation of its technology.
HitIQ Limited announced the resignation of Philip Carulli as a director, effective October 31, 2025. The notice details Carulli’s interests in the company’s securities, including fully paid ordinary shares and listed options, indicating a significant stake. This change in directorship may impact the company’s governance and strategic direction, influencing stakeholder confidence and market perception.
HitIQ Limited has announced the appointment of Anthony (Tony) Peter Toohey as a director, effective from October 31, 2025. The company has disclosed that Mr. Toohey currently holds no relevant interests in securities, either as a registered holder or through contracts, indicating a fresh start in his role with the company.
HitIQ Limited has achieved significant milestones in the September 2025 quarter, including securing an order for 100 PROTEQT™ mouthguards for the Winter Olympics, marking its first Olympic deployment. The company is also undergoing an independent assessment by the International Federation of Sports Medicine (FIMS) for potential global adoption of its technology. Additionally, HitIQ has launched its product in the UK consumer market, integrating with NHS 111 telehealth services, and appointed former AFL player Nathan Murphy as a brand ambassador to enhance visibility in grassroots sports. These developments position HitIQ for broader international expansion and increased credibility in the sports safety industry.
HitIQ Limited has released a proxy voting form for its upcoming Annual General Meeting scheduled for November 28, 2025. The document outlines the procedures for shareholders to appoint proxies and vote on various resolutions, including the adoption of a remuneration report and the election of directors. This announcement is significant as it provides shareholders with the necessary information to participate in the governance of the company, potentially impacting future strategic decisions and company operations.
HitIQ Limited has announced its 2025 Annual General Meeting, which will be held on November 28, 2025, at 3.30pm AEDT. The meeting will be conducted in a hybrid format, allowing shareholders to participate either in-person or online, with provisions for pre-registration and proxy voting. This approach reflects the company’s commitment to accessibility and shareholder engagement, potentially strengthening its relationship with stakeholders.
HitIQ Limited has announced its upcoming Annual General Meeting, which will be held both online and in person. The meeting will address several key resolutions, including the adoption of the remuneration report, the election and re-election of directors, and the approval of a mandate to issue equity securities. These resolutions are crucial for the company’s governance and future strategic decisions, potentially impacting shareholder value and company operations.
HITIQ Limited announced the appointment of Tony Toohey as a Non-Executive Director, replacing Phil Carulli, effective October 31, 2025. This change marks a complete refresh of the Board since November 2023. Mr. Toohey brings extensive experience in gaming, hospitality, leisure, and technology industries, which is expected to enhance the company’s strategic oversight and growth as it pivots towards the consumer market. Mr. Carulli, who has been instrumental in the company’s journey from its inception to its IPO and commercialization of its concussion management system, will transition his accounting and bookkeeping services over the next three months. The leadership transition is seen as a strategic move to support HITIQ’s continued growth and success.
HitIQ Limited announced that its Executive Chair, Earl Eddings, and Non-Executive Director, Matthew Clayworth, will be conducting a roadshow in the US to engage with potential investors and customers. This initiative aims to expand HitIQ’s market presence and attract investment, potentially strengthening its position in the concussion management industry.
HitIQ Limited has announced the quotation of 2,150,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 8, 2025. This move is part of the company’s strategy to enhance its market presence and provide liquidity for its securities, potentially impacting its operational capacity and market positioning positively.
HitIQ Limited announced a change in the director’s interest, specifically regarding Earl Eddings, who has acquired additional unlisted ordinary shares under the company’s Equity Incentive Plan. This change reflects the vesting of shares after 12 months of continuous service, increasing Mr. Eddings’ total holdings in the company. The announcement highlights the company’s commitment to aligning director interests with company performance, potentially impacting investor confidence and stakeholder engagement.
HitIQ Limited has announced a change in the director’s interest, with James Barrie acquiring an additional 100,000 fully paid ordinary shares. This acquisition, valued at $2,100, reflects a direct interest and increases Barrie’s total holdings to 1,573,345 shares. The transaction was conducted on the market, indicating confidence in the company’s future prospects and potentially impacting investor perceptions positively.
HitIQ Limited announced a change in the director’s interest, with Matthew Clayworth acquiring an additional 300,000 fully paid ordinary shares on the market, valued at $6,300. This acquisition reflects a strategic move within the company, potentially strengthening its leadership’s commitment and influence, which may impact the company’s operations and stakeholder confidence.
HitIQ Limited has issued 1,363,637 fully paid ordinary shares and 681,819 options to fulfill a $30,000 obligation for investor relations services. This strategic move, executed without the need for disclosure under certain provisions of the Corporations Act, reflects the company’s compliance with regulatory requirements and its commitment to maintaining transparency with stakeholders.
HitIQ Limited has announced the quotation of new securities on the Australian Securities Exchange (ASX). The company is issuing 681,819 options expiring in December 2028 and 1,363,637 fully paid ordinary shares. This move is part of a previously announced transaction and reflects HitIQ’s ongoing efforts to enhance its market presence and operational capabilities.
HitIQ Limited has announced a change in the director’s interest, with Earl Eddings acquiring an additional 50,000 listed ordinary shares on the market, bringing his total to 12,518,096 shares. This acquisition reflects a modest increase in Eddings’ stake in the company, potentially indicating confidence in HitIQ’s future prospects and stability, which could positively influence stakeholder perceptions and market positioning.
HitIQ Limited, listed on the ASX under the ticker HIQ, has announced the issuance of 11,363,637 fully paid ordinary shares and 5,681,819 options as part of a placement that raised $250,000. This issuance was conducted without disclosure to the holders under Part 6D.2 of the Corporations Act 2001, and the company has confirmed compliance with relevant provisions of the Act. The announcement reflects HitIQ’s ongoing efforts to secure funding and potentially enhance its market position, with implications for its operational capacity and stakeholder interests.
HitIQ Limited has announced the quotation of new securities on the Australian Securities Exchange (ASX), comprising 5,681,819 options expiring on December 30, 2028, and 11,363,637 fully paid ordinary shares. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially impacting its market positioning and providing opportunities for growth and expansion in the sports safety technology sector.
HitIQ Limited has announced a proposed issue of securities, including 681,819 options expiring on December 30, 2028, and 1,363,637 fully paid ordinary shares. This initiative is part of a placement or other type of issue, with the proposed issue date set for October 3, 2025. The issuance is expected to support the company’s operations and potentially strengthen its position in the market by providing additional capital.
HITIQ Limited, a company listed on the Australian Securities Exchange (ASX: HIQ), has announced the issuance of shares and attaching options to its Investor Relations service provider as a form of payment for services rendered. This move aligns with HITIQ’s strategy to prioritize capital allocation towards business operations. The issuance involves 1,363,637 shares at a price of $0.022 per share and 681,819 options, exercisable at the same price, with an expiration date of December 30, 2028. This decision reflects the company’s ongoing efforts to manage its financial resources efficiently.
HitIQ Limited has announced a proposed issue of securities, including 5,681,819 options expiring in December 2028 and 11,363,637 fully paid ordinary shares. This move is aimed at raising capital to support the company’s growth and operational strategies, potentially strengthening its market position in the sports technology sector.
HitIQ Limited has released a presentation that provides an overview of its operations and strategic intentions, though it is not intended as a financial product offer or recommendation. The document emphasizes that the information is prepared in good faith but does not guarantee accuracy or completeness, highlighting potential risks and uncertainties that could affect future performance.
HitIQ Limited is hosting a shareholder update webinar to discuss its strategic shift towards the consumer market and the commercial rollout of its product, PROTEQT™. This move is expected to enhance the company’s market positioning by broadening its consumer base and potentially increasing its market share in the concussion management industry.